WallStSmart

Alcon AG (ALC)vsPro-Dex Inc (PDEX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 14326% more annual revenue ($10.40B vs $72.10M). PDEX leads profitability with a 15.7% profit margin vs 9.4%. PDEX trades at a lower P/E of 14.1x. PDEX earns a higher WallStSmart Score of 53/100 (C-).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

PDEX

Buy

53

out of 100

Grade: C-

Growth: 6.7Profit: 8.5Value: 8.3Quality: 9.5
Piotroski: 6/9Altman Z: 4.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
PDEXUndervalued (+44.0%)

Margin of Safety

+44.0%

Fair Value

$67.93

Current Price

$48.61

$19.32 discount

UndervaluedFair: $67.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

PDEX4 strengths · Avg: 9.3/10
Return on EquityProfitability
30.9%10/10

Every $100 of equity generates 31 in profit

Altman Z-ScoreHealth
4.1410/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

P/E RatioValuation
14.1x8/10

Attractively priced relative to earnings

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

PDEX1 concerns · Avg: 3.0/10
Market CapQuality
$156.41M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : PDEX

The strongest argument for PDEX centers on Return on Equity, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 15.7% and operating margin at 17.5%. Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : PDEX

The primary concerns for PDEX are Market Cap.

Key Dynamics to Monitor

ALC profiles as a value stock while PDEX is a mature play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

PDEX is growing revenue faster at 11.1% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

PDEX scores higher overall (53/100 vs 49/100), backed by strong 15.7% margins and 11.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Pro-Dex Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.

Want to dig deeper into these stocks?